

INTERNATIONAL SEARCH REPORT

Int nal Application No
PCT/EP2004/010686

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K45/06 A61K31/502

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/55114 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H; MANLE) 2 August 2001 (2001-08-02) page 14, paragraph 2 page 15, line 2	1,2,4,5, 8,10,11, 13,14, 17,19
X	WO 02/066470 A (AMGEN INC) 29 August 2002 (2002-08-29) pages 5-6; claims 1,19,20,35-47,56,57 pages 73-74 pages 93-101 page 98, line 34 page 99, lines 11-13 ----- -/-	1,2,4,5, 7,8,10, 11,13, 14,16, 17,19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

19 April 2005

Date of mailing of the international search report

29. 07. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kanbier, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/010686

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 03/047586 A (SCHERING CORPORATION) 12 June 2003 (2003-06-12)</p> <p>page 26; claims 1,34,35 -----</p>	<p>1,4,7, 10,13, 16,19</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2004/010686

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-9 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an aromatase inhibitor; as well as compositions and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound which does not fall within formulas (I), (II) or (III) and a chemotherapeutic agent as listed in claims 1, 4, 7, 10, and/or 13.

2. claims: Partly 1, 2, 5, 8, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an antiestrogen, antiandrogen or gonadorelin antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

3. claims: Partly 1, 2, 5, 8, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a topoisomerase I or -II inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

4. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a microtubule active compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

5. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an alkylating- or DNA alkylating compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an anti-neoplastic antimetabolite compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

7. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a platin compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

8. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a compound targeting / decreasing a protein or lipid kinase activity, including SRC inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

9. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a compound targeting / decreasing a protein or lipid phosphatase activity, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

10. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a further anti-angiogenic compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

11. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a compound which induces cell differentiation processes, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

12. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a bradykinin 1 receptor antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

13. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an angiotensin II antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

14. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a cyclooxygenase- or COX-2 inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

15. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a bisphosphonate compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

16. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a heparanase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

17. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a biological response modifying compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

18. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an ubiquitination inhibiting compound excluding HSP90 inhibiting degraders, targeters, decreasors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

19. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an inhibiting compound that blocks anti-apoptotic pathways, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

20. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an inhibiting compound of Ras-oncogenic isoforms, including farnesyl transferase inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

21. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a telomerase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

22. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a protease inhibiting compound, namely a matrix metalloproteinase inhibitor, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

23. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a protease inhibiting compound, namely a methionine aminopeptidase inhibitor, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

24. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a protease inhibiting compound, namely a proteasome inhibitor, excluding HSP90 inhibiting degraders, targeters, decreasors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

25. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a compound used in the treatment of hematologic malignancies or FMS-like tyrosine kinase inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

26. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an HSP90 inhibiting compound, including HDAC inhibitors and including HSP90 inhibiting degraders, targeters, decreasers or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

27. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an mTOR inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

28. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an somatostatin receptor antagonising compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

29. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an integrin antagonising compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

30. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an antileukemic compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

31. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a tumor cell damaging approach, e.g. ionizing radation.

32. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an EDG binding compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

33. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an anthranilic acid amide class of kinase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

34. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a ribonucleotide reductase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

35. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an S-adenosyl methionine decarboxylase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

36. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is a compound that is an antibody against VEGF or VEGFR, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

37. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and photodynamic therapy.

38. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an angiostatic steroid compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

39. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an implant containing a corticosteroid compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

40. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an AT1 receptor antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

41. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (I) and a chemotherapeutic agent which is an ACE inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention.

42. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an aromatase inhibitor.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

43. claims: Partly 1, 2, 5, 8, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an antiestrogen, antiandrogen or gonadorelin antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

44. claims: Partly 1, 2, 5, 8, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a topoisomerase I or -II inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

45. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a microtubule active compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

46. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an alkylating- or DNA alkylating compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

47. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an anti-neoplastic antimetabolite compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

48. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a platin compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

49. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a compound targeting / decreasing a protein or lipid kinase activity, including SRC inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

50. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a compound targeting / decreasing a protein or lipid phosphatase activity, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

51. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a further anti-angiogenic compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

52. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a compound which induces cell differentiation processes, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

53. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a bradykinin 1 receptor antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

54. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an angiotensin II antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

55. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a cyclooxygenase- or COX-2 inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

56. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a bisphosphonate compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

57. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a heparanase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

58. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a biological response modifying compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

59. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an ubiquitination inhibiting compound excluding HSP90 inhibiting degraders, targeters, decreaseors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

60. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an inhibiting compound that blocks anti-apoptotic pathways, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

61. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an inhibiting compound of Ras-oncogenic isoforms, including farnesyl transferase inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

62. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a telomerase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

63. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a protease inhibiting compound, namely a matrix metalloproteinase inhibitor, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

64. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a protease inhibiting compound, namely a methionine aminopeptidase inhibitor, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

65. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a protease inhibiting compound, namely a proteasome inhibitor, excluding HSP90 inhibiting degraders, targeters, decreaseors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

66. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a compound used in the treatment of hematologic malignancies or FMS-like tyrosine kinase inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

67. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an HSP90 inhibiting compound, including HDAC inhibitors and including HSP90 inhibiting degraders, targeters, decreaseors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

68. claims: Partly 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an mTOR inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

69. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an somatostatin receptor antagonising compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

70. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an integrin antagonising compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding invention 1-41.

71. claims: Partly 1, 2, 5, 7, 8, 10, 11, 14, 16, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an antileukemic compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

72. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a tumor cell damaging approach, e.g. ionizing radiation.

73. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an EDG binding compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

74. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an anthranilic acid amide class of kinase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

75. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a ribonucleotide reductase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

76. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an S-adenosyl methionine decarboxylase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

77. claims: Partly 1, 2, 4, 5, 8, 10, 11, 13, 14, 17, 19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is a compound that is an antibody against VEGF or VEGFR, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

78. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and photodynamic therapy.

79. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an angiostatic steroid compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

80. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an implant containing a corticosteroid compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

81. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an AT1 receptor antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

82. claims: Partly 1, 2, 5, 8, 10, 11, 14, 17, 19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (II) and a chemotherapeutic agent which is an ACE inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-41.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

83. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an aromatase inhibitor.

84. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an antiestrogen, antiandrogen or gonadorelin antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

85. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a topoisomerase I or -II inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

86. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a microtubule active compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

87. claims: Partly 1-3, 5-12, 14-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an alkylating- or DNA alkylating compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

88. claims: Partly 1-3, 5-12, 14-19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an anti-neoplastic antimetabolite compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

89. claims: Partly 1-3, 5-12, 14-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a platin compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

90. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a compound targeting / decreasing a protein or lipid kinase activity, including SRC inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

91. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a compound targeting / decreasing a protein or lipid phosphatase activity, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

92. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a further anti-angiogenic compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

93. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a compound which induces cell differentiation processes, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

94. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a bradykinin 1 receptor antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

95. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an angiotensin II antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

96. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a cyclooxygenase- or COX-2 inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

97. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a bisphosphonate compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

98. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a heparanase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

99. claims: Partly 1-3, 5-12, 14-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a biological response modifying compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

100. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an ubiquitination inhibiting compound excluding HSP90 inhibiting degraders, targeters, decreaseors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

101. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an inhibiting compound that blocks anti-apoptotic pathways, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

102. claims: Partly 1-6, 8-15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an inhibiting compound of Ras-oncogenic isoforms, including farnesyl transferase inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

103. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a telomerase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

104. claims: Partly 1-6, 8-15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a protease inhibiting compound, namely a matrix metalloproteinase inhibitor, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

105. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a protease inhibiting compound, namely a methionine aminopeptidase inhibitor, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

106. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a protease inhibiting compound, namely a proteasome inhibitor, excluding HSP90 inhibiting degraders, targeters, decreaseors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

107. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a compound used in the treatment of hematologic malignancies or FMS-like tyrosine kinase inhibitors, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

108. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an HSP90 inhibiting compound, including HDAC inhibitors and including HSP90 inhibiting degraders, targeters, decreaseors or inhibitors of the HSP90 client proteins via the ubiquitin proteasome pathway, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

109. claims: Partly 1-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an mTOR inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

110. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an somatostatin receptor antagonising compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

111. claims: Partly 1-3, 5, 6, 8-2, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an integrin antagonising compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding invention 1-82.

112. claims: Partly 1-3, 5-12, 14-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an antileukemic compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

113. claims: Partly 1-6, 8-15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a tumor cell damaging approach, e.g. ionizing radiation.

114. claims: Partly 1-6, 8-15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an EDG binding compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

115. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19.

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an anthranilic acid amide class of kinase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

116. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a ribonucleotide reductase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

117. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an S-adenosyl methionine decarboxylase inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

118. claims: Partly 1-6, 8-15, 17-19

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is a compound that is an antibody against VEGF or VEGFR, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

119. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and photodynamic therapy.

120. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an angiostatic steroid compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

121. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an implant containing a corticosteroid compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

122. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an AT1 receptor antagonist compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

123. claims: Partly 1-3, 5, 6, 8-12, 14, 15, 17-19

Compositions, and uses thereof for treatments of proliferative diseases, comprising a VEGF inhibiting compound of formula (III) and a chemotherapeutic agent which is an ACE inhibiting compound, the latter compound not falling within the scope of chemotherapeutic agents defined in an earlier invention, excluding inventions 1-82.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Ir 1al Application No
PCT/EP2004/010686

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0155114	A	02-08-2001	AU 771626 B2	01-04-2004
			AU 2849901 A	07-08-2001
			BR 0107805 A	22-10-2002
			CA 2396590 A1	02-08-2001
			CN 1396912 A	12-02-2003
			CZ 20022582 A3	16-10-2002
			WO 0155114 A1	02-08-2001
			EP 1259487 A1	27-11-2002
			HU 0204083 A2	28-03-2003
			JP 2003520853 T	08-07-2003
			MX PA02007319 A	29-11-2002
			NO 20023218 A	16-09-2002
			NZ 520005 A	27-02-2004
			PL 356307 A1	28-06-2004
			SK 10852002 A3	02-05-2003
			US 2003032656 A1	13-02-2003
			ZA 200205988 A	28-07-2003
WO 02066470	A	29-08-2002	US 2003125339 A1	03-07-2003
			BG 108012 A	30-11-2004
			BR 0206435 A	23-09-2003
			CA 2434277 A1	29-08-2002
			CZ 20031863 A3	14-07-2004
			EE 200300324 A	15-12-2003
			EP 1358184 A1	05-11-2003
			HU 0302598 A2	28-11-2003
			JP 2004531484 T	14-10-2004
			MX PA03006179 A	11-12-2003
			NO 20033181 A	11-09-2003
			NZ 526868 A	29-04-2005
			SK 8582003 A3	03-08-2004
			WO 02066470 A1	29-08-2002
			US 2003225106 A1	04-12-2003
			ZA 200305197 A	19-03-2004
WO 03047586	A	12-06-2003	AU 2002346644 A1	17-06-2003
			CA 2468996 A1	12-06-2003
			EP 1453513 A1	08-09-2004
			JP 2005515201 T	26-05-2005
			WO 03047586 A1	12-06-2003
			US 2004006087 A1	08-01-2004